C677T POLYMORPHISM IN THE METHYLENETETRAHYDROFOLATE REDUCTASE GENE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

Abstract

The aimof the study was to identify clinical and laboratory features of the disease in patients with myocardial infarction with ST-segment elevation and C677T polymorphism in the methylenetetrahydrofolate reductase gene.Material and Methods. A total of 81 patients with ST-segment elevation myocardial infarction were examined. Clinical, laboratory, instrumental, and statistical methods were used.Conclusion. Among patients with ST-segment elevation myocardial infarction, the proportion of persons with homozygous carriership of polymorphic alleles in the MTHFR gene was 30% (genotype 677СС); and 58.02% (genotype 677СT) of patients were heterozygous carriers. Patients with homozygous carriership of polymorphic alleles in the MTHFR gene were characterized by higher values of Big endothelin-1 and homocysteine in serum compared with persons with genotype 677СС: 10.7 (4.5–14.5) pg/mL, 27 (20–28) μmol/L, and 2.7 (2.2–3.8) pg/mL, and 17 (14–20) μmol/L, respectively, p<0.05. A positive moderate force correlation was found between the carriership of polymorphic alleles MTHFR C677T and homocysteine levels (r=0.42, p<0.05) and Big endothelin-1 (r=0.45, p<0.05) in the cohort under study. In patients with homozygous carriership of polymorphic alleles in the MTHFR gene, myocardial infarction was significantly more often complicated by the development of recurrent coronary events in comparison with groups with heterozygous carriership and the absence of polymorphic alleles in this gene: 88.9% (n=8) versus 42.55% (n=20), χ2=6.5, p<0.05 and 28% (n=7), χ2=10.0, p<0.01 respectively.